GLOBAL CANCER TECHNOLOGY

PRESS RELEASE

For Immediate Release

Contact:
info@globalcancertechnology.com

GLOBAL CANCER TECHNOLOGY FILES TO EXPAND IP PORTFOLIO

Patent Application Covers Growing Area in Cancer Treatment

San Diego, CA October 16, 2024-Global Cancer Technology announced that it has filed National Stage Patent Applications in 12 major world markets. The published PCT patent application, WO/2023/196899 "METHODS AND PRODUCTS TO SCREEN AND TREAT GLIOBLASTOMA MULTIFORME AND OTHER CANCERS, INCLUDING BREAST CANCERS, USING A COMBINATION OF PI3KINASE INHIBITORS WITH CHECKPOINT INHIBITORS" can have far reaching effects in a rapidly developing biopharma area of interest.

"Global Cancer Technology is dedicated to expanding its IP protection of its various drug assets, and this is an important step in achieving that protection" said John Clark, the Founder & CEO of Global Cancer Technology. Mr. Clark further stated 'Our preclinical data indicate that our novel PI3K small molecule (GCT-007) could work synergistically with checkpoint inhibitors to reduce tumor burden and make the disease more treatable. The approach of combining conventional small molecule drugs, like PI3K inhibitors, with immunotherapies can significantly change the way cancer, and other diseases are treated, and can create large market opportunities for our drug."

Checkpoint inhibitors have recently become more widely used in treating cancer, expanding the range of options for cancer patients. However, many forms of cancer are not responsive to immunotherapies because the tumor is effective in evading or hiding from the patient's immune system. By first using a drug like Global Cancer Technology's GCT-007 the tumor is better able to signal the patient's immune system and be responsive to immunotherapy.

Global Cancer Technology (GCT) is a pre-revenue biopharma holding company developing a single PI3K inhibitor drug to treat both glioblastoma and triple-negative breast cancer (TNBC).